ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of LUMIGAN® RC in the Clinical Setting

Phase 4

Completed

Conditions: Glaucoma, Primary Open Angle
Ocular Hypertension

Interventions: Drug: Bimatoprost 0.01%

First Posted Date: 2013-04-17

Last Posted Date: 2013-09-26

Lead Sponsor: Allergan

Target Recruit Count: 1137

Registration Number: NCT01833741

Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)

Phase 4

Completed

Conditions: Chronic Migraine

Interventions: Biological: OnabotulinumtoxinA
Drug: Normal saline (placebo)

First Posted Date: 2013-04-16

Last Posted Date: 2015-10-21

Lead Sponsor: Allergan

Target Recruit Count: 52

Registration Number: NCT01833130

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Bimatoprost 0.03%
Drug: Bimatoprost 0.01%

First Posted Date: 2013-04-12

Last Posted Date: 2015-05-06

Lead Sponsor: Allergan

Target Recruit Count: 466

Registration Number: NCT01830140

Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

Phase 2

Terminated

Conditions: Interstitial Cystitis

Interventions: Other: LiRIS Placebo
Drug: LiRIS 400 mg

First Posted Date: 2013-04-04

Last Posted Date: 2016-01-26

Lead Sponsor: Allergan

Target Recruit Count: 31

Registration Number: NCT01824303

Locations: 🇺🇸
North Shore - Long Island Jewish Heath System - Monter Cancer Center, New Hyde Park, New York, United States
🇺🇸
Citrus Valley Medical Research , Inc., Glendora, California, United States
🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States

and more 13 locations

Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classification

Completed

Conditions: Healthy Volunteers

Interventions: Other: No Intervention

First Posted Date: 2013-04-01

Last Posted Date: 2014-04-30

Lead Sponsor: Allergan

Target Recruit Count: 201

Registration Number: NCT01821534

A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm

Completed

Conditions: Blepharospasm
Cervical Dystonia

Interventions: Other: No Intervention

First Posted Date: 2013-03-20

Last Posted Date: 2014-07-03

Lead Sponsor: Allergan

Target Recruit Count: 48

Registration Number: NCT01814774

Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines

Phase 4

Completed

Conditions: Glabellar Rhytides

Interventions: Biological: botulinum toxin Type A

First Posted Date: 2013-03-20

Last Posted Date: 2019-04-17

Lead Sponsor: Allergan

Target Recruit Count: 185

Registration Number: NCT01814670

A Study of Bimatoprost 0.01% in the Clinical Setting

Completed

Conditions: Ocular Hypertension
Glaucoma, Primary Open Angle

Interventions: Drug: Bimatoprost 0.01%

First Posted Date: 2013-03-20

Last Posted Date: 2015-10-26

Lead Sponsor: Allergan

Target Recruit Count: 312

Registration Number: NCT01814761

A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema

Completed

Conditions: Macular Edema

Interventions: Drug: Dexamethasone Intravitreal Implant

First Posted Date: 2013-03-06

Last Posted Date: 2019-04-17

Lead Sponsor: Allergan

Target Recruit Count: 101

Registration Number: NCT01805323

BOTOX® in the Treatment of Crow's Feet Lines in Japan

Phase 3

Completed

Conditions: Lateral Canthus Rhytides
Crow's Feet Lines

Interventions: Biological: botulinum toxin Type A (24 U)
Biological: botulinum toxin Type A (12 U)
Other: Normal Saline

First Posted Date: 2013-02-22

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 300

Registration Number: NCT01797081

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy